Clinical Trial Update: Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP) [Phase 3]

View source ↗

Summary

An extensionPhase 3 trial evaluated long-term safety and efficacy of IONIS-TTR Rx in familial amyloid polyneuropathy, with completed status and results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Amyloid Polyneuropathy
• Transthyretin Amyloidosis

Drugs mentioned

• IONIS-TTR Rx (IONIS-TTR Rx)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: FAP, Familial Amyloid Polyneuropathy | Phase 3 | Status: COMPLETED | Results posted: 2023-02-09